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Subtotal hepatectomy and whole graft auxiliary transplantation for
acetaminophen-associated acute liver failure
The legend of Prometheus that first documented the extraordinary capacity of the liver to regenerate is familiar to
liver surgeons. Major liver resection relies on this regenerative capacity of the liver to restore volume and function
after surgery. Acetominophen toxicity (paracetomol) causes widespread hepatocyte necrosis but we know from
animal models and human survivors that complete hepatic regeneration is possible. The time to allow liver
regeneration is unfortunately too slow for many patients who will either die or require urgent liver transplantation
to avoid the consequences of severe acute liver failure. In this edition of HPB, the Leeds group present a series of
patients who have beenmanaged in an extraordinary way. These patients who all had acute liver failure and whomet
criteria for urgent transplantation (which equates to a near 90% mortality without transplantation),underwent a
right trisegmentectomy, preserving segments 1,2 & 3 and then underwent a reduced or split graft right lobe auxiliary
liver transplant. After recovering from the procedure a HIDA scan was performed to test regeneration and function
in the native remnant liver and then immunosuppression was gradually withdrawn over a 6–12 month period
resulting in atrophy of the transplanted liver and compensatory hypertrophy of the native liver. This innovative
approach to liver transplantation has allowed a resurrection of what by many would be considered an irretrievably
damaged liver. The avoidance of the need for long term immunosuppression in what is usually a young population
may contribute in part to the better 5 year survival in patients. This is however, a technical tour de force and it will
be interesting to see if other centres are persuaded to give it a go.
Stephen J Wigmore
Lymph node(LN) 16b1 – the importance of knowing when to stop
Gallbladder cancer has a terrible prognosis and avoiding futile morbid interventions on patients who will not
benefit is an important role of the HPB surgeon. LN16b1 is the nodal group that lies in the aortocaval groove
between the SMA and IMA. Involvement of LN16b1 by metastatic disease in patients with gallbladder cancer has
been shown to be associated with a prognosis equivalent to that of distant or widespread metastatic disease which
should be considered as incurable. In this issue of HPB, Agarwal et al., describe their extensive experience with
gallbladder cancer in some 450 patients over a 2 year period. The aim of this prospective study was to analyse the
incidence of LN 16b1 involvement in patients presenting with gallbladder cancer. Of the 251 (55.7%) patients who
were deemed to be resectable following radiological staging, 68 (27.1%) were found to have disseminated disease at
laparoscopy and thus 183 underwent LN16b1 biopsy at laparotomy. Of these, 34 (18.6%) were LN16b1 positive and
did not undergo resection. A further 7 (4.7%) did not undergo resection due to locally advanced disease. Thus from
a total of 451 patients only 142 (31.5%) underwent potentially curative resection. These figures are a stark reminder
of the limitations of surgery in the treatment of this disease. I would strongly recommend this paper to surgeons
who deal with gallbladder cancer especially those from countries where the incidence is low. Much can be learnt
from spending time reading the details of this paper. They highlight that preoperative radiological assessment of
nodal involvement is inaccurate and therefore on its own unhelpful although endoscopic ultrasound was not part
of the work up. Fine needle aspiration of LN16b1 has a significant false negative rate and therefore the authors
would encourage the use of frozen section at the time of laparotomy prior to resection. Furthermore, frozen section
of LN16b1 in an experienced centre is very accurate and can be used to abort the resection should it be positive.
Whether a similar accuracy can be replicated in lower volume centres remains to be seen.
Saxon Connor
A case for aggressive reoperation
Locoregional and metastatic recurrence after successful resection of periampullary cancer sadly occurs in the
majority of patients despite R0 resections and aggressive adjuvant therapy. Reoperation is rarely considered because
of the extent of disease, and perhaps a prevailing dogma of futility. Should this remain the case? After all, today’s new
chemotherapy regimens may be shifting the curves for tumor response and survival in some, based on tumor
biology. Boone et al. report outcomes for 22 patients (over 21 years) who underwent reoperative resection for locally
recurrent or isolated metastatic periampullary cancer. Ten patients (45%) underwent reoperation for local recur-
rence, and 12 (55%) underwent resections of metastases (6- liver, 5-lung, 1-ovary). Perioperative outcomes com-
pared favorably between the two stages of resection, but overall complication rates (32%) were in fact lower for
reoperations. There was no perioperative mortality.Median survival after reoperation was an impressive 28 months,
and was significantly longer if the interval between primary resection and reoperation exceeded 15 months (40.6 vs
8.2 months). Six patients remain alive at their last follow-up. Univariate analysis seeking to identify which patients
would benefit most from this reoperative strategy was unrevealing, probably due to the small sample size. Admit-
tedly, the success stories are few and sporadic. However, this fine series indicates that a reoperation strategy can be
feasible and safe. A patient 4 years out from reoperation for isolated liver recurrence kindly sent me a recent holiday
text-photo, smiling in the Florida sunshine, subcostal incision and all. Another compelling case for aggressive
reoperation.
Mark Callery
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